Consistent with our results, in left-sided tumors, TP53 (L_cancer: 68%, R_cancer: 48%) showed a higher mutation rate; meanwhile, in right-sided tumors, PIK3CA (L_cancer: 18%, R_cancer: 33%) and KRAS (L_cancer: 36%, R_cancer: 46%) showed higher yield mutation rates. This evidence concerns the gene TP53 and cancer.